
Profit halved, growth stalled—the capex bet is now the story
Arclin concentration · capex execution · product pipeline risk
BSE: 506687
P/L Snapshot
Q1 FY27 · standalone
Shareholding
Pattern breakdown
P/L Trends
(in crores)

Arclin concentration · capex execution · product pipeline risk

product diversification · margin pressure · capacity constraints

specialty chemicals · margin compression · profit decline
Corporate Events
Board Meeting
The Annual General Meeting of the Company is scheduled to be…
BSE Filing ↗Board Meeting
The meeting of the Board of Directors of the Company will be…
BSE Filing ↗Board Meeting
The board meeting is scheduled to consider and approve the A…
BSE Filing ↗Board Meeting
Consider and approve the Audited Standalone and Consolidated…
BSE Filing ↗Board Meeting
Consider and approve Audited Financial Statements for the fo…
BSE Filing ↗Board Meeting
Consider and approve Unaudited Financial Results for the qua…
BSE Filing ↗Board Meeting
Consider and approve Unaudited Results for the quarter ended…
BSE Filing ↗